Prognostic factors influencing outcome after therapy with brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma

Goranova-Marinova, Vesselina; Ignatova, Kalina; Ganeva, Penka; Spasov, Emil; Arnaudov, G.; Micheva, Ilina; Gercheva, Liana; Radinov, Atanas; Petrova, Raya; Tzvetkova, Gergana; Hadzhiev, E.; L, Bogdanov; Tzvetkov, Nikolay; Spasov, B.; Грудева-Попова, Жанет; Tumbeva, Dora Y

doi:10.1093/annonc/mdz251.008

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven of these 12 studies were deemed of good methodological quality [8,14,15,20,22,28,36] and were included in the primary meta-analysis while the remaining five studies were of moderate methodological quality and hence, were only considered for the sensitivity analyses [16,21,26,27,41]. In addition, there were 14 studies which consisted of abstracts or conference proceedings that were included in a second set of sensitivity analyses [17][18][19][23][24][25][29][30][31][32]34,38,39,42].…”

Section: Treatment Responsementioning

confidence: 99%

“…However, since the two studies deemed of good methodological quality [14,33] used different definition of OS, no meta-analysis could be conducted. The first defined OS as the time from BV initiation to death of any cause [14] while the second defined it as the time from relapse/progression after ASCT until death of any cause or last follow-up [23].…”

Section: Survival In R/r Chl Patients Treated With Bvmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis

Plattel

Bergamasco

Trinchese

et al. 2021

Leukemia & Lymphoma

View full text Add to dashboard Cite

This systematic review and meta-analysis aimed to determine the effectiveness of brentuximab vedotin (BV) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) in the clinical practice setting using most recent results. A total of 32 observational studies reporting on treatment patterns, overall response rate (ORR), complete response (CR) rate, progression-free survival (PFS), overall survival (OS), and adverse events were found. After four cycles, a random-effect model yielded pooled ORR and CR rates of 62.6% (95% confidence interval (CI): 56.0-68.9; I 2 ¼ 9.7%) and 32.9% (95% CI, 20.8-46.3, I 2 ¼ 64.8%), respectively. Regarding survival, 1-year, 2-year, and 5year PFS ranged from 52.1% to 63.2%, 45.2% to 56.2%, and 31.9% to 33.0%, respectively. OS rates were 68.2-82.7%, 58.0-81.9%, and 58.0-62.0%, respectively. Most common adverse events were hematological toxicities (neutropenia: 13.3-23%, anemia: 8.8-39.0%, and thrombocytopenia: 4-4.6%), and grade 3 peripheral neuropathy (3.3-7.3%). This study supports the effectiveness and safety of BV in R/R cHL patients in the real-world setting.

show abstract